Alzamend Neuro (ALZN) to Release Earnings on Wednesday

Alzamend Neuro (NASDAQ:ALZN) is anticipated to announce its results before the market opens on Wednesday, December 10th. Analysts expect the company to announce earnings of ($0.83) per share for the quarter.

Alzamend Neuro Price Performance

Alzamend Neuro stock opened at $2.25 on Monday. Alzamend Neuro has a 1 year low of $1.88 and a 1 year high of $12.06. The firm’s 50 day moving average price is $2.33 and its 200-day moving average price is $2.66. The stock has a market cap of $7.07 million, a P/E ratio of -0.34 and a beta of -0.25.

Insider Buying and Selling

In other Alzamend Neuro news, Director Milton C. Ault III sold 101,394 shares of Alzamend Neuro stock in a transaction on Wednesday, October 8th. The shares were sold at an average price of $2.44, for a total value of $247,401.36. Following the completion of the transaction, the director directly owned 28,657 shares of the company’s stock, valued at $69,923.08. This trade represents a 77.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders have sold a total of 661,233 shares of company stock worth $1,584,153 in the last three months. 30.21% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ALZN. Ascendiant Capital Markets reduced their price target on shares of Alzamend Neuro from $45.00 to $42.00 and set a “buy” rating on the stock in a report on Thursday, September 25th. Weiss Ratings restated a “sell (e+)” rating on shares of Alzamend Neuro in a research report on Monday, November 24th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $42.00.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.